Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.45 |
| ▸ | ATR | Q13535 | 8/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.45 |
| ▸ | ATRIP | Q8WXE1 | 7/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.45 |
| ▸ | MTOR | P42345 | 6/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198599 | 0.89 | POLB (0.48) | PIK3CAPIK3CDATRCHEK1PDCD1 | |
| SCHEMBL8092741 | 0.87 | PIK3CA (0.49) | PIK3CAPIK3CDATRCHEK1PDCD1 | |
| SCHEMBL4202707 | 0.85 | PIK3CA (0.51) | PIK3CAPIK3CDATRCHEK1PDCD1 | |
| SCHEMBL4202609 | 0.82 | PIK3CA (0.59) | PIK3CAPIK3CDMTOR | |
| SCHEMBL4203833 | 0.81 | PIK3CA (0.47) | PIK3CAPIK3CDATRCHEK1PDCD1 | |
| SCHEMBL4198807 | 0.81 | ATR (0.54) | PIK3CAATRATRIPMTOR | |
| SCHEMBL4201583 | 0.81 | PIK3CA (0.50) | PIK3CAPIK3CDATRCHEK1PDCD1 | |
| SCHEMBL739607 | 0.81 | PIK3CA (0.52) | PIK3CAPIK3CDATRCHEK1PDCD1 | |
| SCHEMBL3596530 | 0.81 | POLB (0.59) | PIK3CAPIK3CDATRCHEK1PDCD1 | |
| SCHEMBL2487507 | 0.80 | PIK3CA (0.62) | PIK3CAPIK3CDATRCHEK1PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101801962-A | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | ASTRAZENECA AB | 2010-08-11 | — | — | CN | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018134-A1 | Compounds - 945 | MTOR, PIK3CA, PIK3R5 | PIK3CA 2/4885PIK3CD 4/4885ATR 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.